BORTEZOMIB (VEL) BASED REGIMENS IN MULTIPLE MYELOMA (MM) PATIENTS WITH RENAL IMPAIRMENT (RI): A PRELIMINARY RETROSPECTIVE ITALIAN MULTICENTER STUDY

被引：0
|
作者：
Gentile, M. [1 ]
Ciolli, S. [2 ]
Petrucci, M. T. [3 ]
Galimberti, S. [4 ]
Mele, G. [5 ]
Casulli, A. F.
Mannina, D. [6 ]
Piro, E. [7 ]
Morabito, F. [1 ]
机构：
[1] Ematol Cosenza, Cosenza, Italy
[2] Univ & Osped Careggi, Dipartimento Ematol, Florence, Italy
[3] Univ Roma La Sapienza, Dipartimento Biotecnol & Ematol, Rome, Italy
[4] Osped Santa Chiara, Sez Ematol, Dipartimento Oncol, Pisa, Italy
[5] Presidio Osped A Perrino, Div Ematol, Brindisi, Italy
[6] Azienda Osped Papardo, Div Ematol, Taranto, Italy
[7] Osped Pugliese Ciaccio, Div Ematol, Catanzaro, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0210
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study
    Gentile, Massimo
    Ciolli, Stefania
    Petrucci, Maria Teresa
    Galimberti, Sara
    Mele, Giuseppe
    Casulli, Antonio Francesco
    Mannina, Donato
    Piro, Eugenio
    Pinotti, Graziella
    Palmieri, Salvatore
    Catalano, Lucio
    Callea, Vincenzo
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Baldini, Luca
    Tosi, Patrizia
    Di Raimondo, Francesco
    Boccadoro, Mario
    Palumbo, Antonio
    Cavo, Michele
    Morabito, Fortunato
    BLOOD, 2008, 112 (11) : 1260 - 1261
  • [2] Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
    Morabito, Fortunato
    Gentile, Massimo
    Ciolli, Stefania
    Petrucci, Maria T.
    Galimberti, Sara
    Mele, Giuseppe
    Casulli, Antonio F.
    Mannina, Donato
    Piro, Eugenio
    Pinotti, Graziella
    Palmieri, Salvatore
    Catalano, Lucio
    Callea, Vincenzo
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Baldini, Luca
    Tosi, Patrizia
    Di Raimondo, Francesco
    Boccadoro, Mario
    Palumbo, Antonio
    Cavo, Michele
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (03) : 223 - 228
  • [3] Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
    Chanan-Khan, Asher A.
    Kaufman, Jonathan L.
    Mehta, Jayesh
    Richardson, Paul G.
    Miller, Kena C.
    Lonial, Sagar
    Munshi, Nikhil C.
    Schlossman, Robert
    Tariman, Joseph
    Singhal, Seema
    BLOOD, 2007, 109 (06) : 2604 - 2606
  • [4] Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors
    Dimopoulos, Meletios A.
    Roussou, Maria
    Kastritis, Efstathios
    Gavriatopoulou, Maria
    Zagouri, Flora
    Migkou, Magdalini
    Matsouka, Charis
    Barmparousi, Despina
    Christoulas, Dimitrios
    Psimenou, Erasmia
    Grapsa, Irini
    Terpos, Evangelos
    BLOOD, 2008, 112 (11) : 607 - 608
  • [5] Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors
    Dimopoulos, Meletios A.
    Roussou, Maria
    Gavriatopoulou, Maria
    Zagouri, Flora
    Migkou, Magdalini
    Matsouka, Charis
    Barbarousi, Despina
    Christoulas, Dimitrios
    Primenou, Erasmia
    Grapsa, Irini
    Terpos, Evangelos
    Kastritis, Efstathios
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (04): : 302 - 306
  • [6] EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS
    Chen, W.
    Lu, J.
    Hou, J.
    HAEMATOLOGICA, 2013, 98 : 340 - 341
  • [7] Treatment of patients with multiple myeloma complicated by renal failure with bortezomib - Based regimens
    Roussou, Maria
    Kastritis, Efstathios
    Anagnostopoulos, Athanasios
    Psimenou, Erasinia
    Grapsa, Irini
    Matsouka, Charis
    Barmparousi, Despina
    Terpos, Evangelos
    Dimopoulos, Meletios Athanasios
    BLOOD, 2007, 110 (11) : 805A - 805A
  • [8] Renal dysfunction does not affect clinical response in multiple myeloma (MM) patients treated with bortezomib-based regimens
    Ailawadhi, Sikander
    Mashtare, Terry L.
    Coignet, Marie V.
    Depaolo, Dawn M.
    Miller, Kena C.
    Wilding, Gregory
    Chanan-Khan, Asher Alban
    BLOOD, 2007, 110 (11) : 442A - 442A
  • [9] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [10] Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
    Roussou, Maria
    Kastritis, Efstathios
    Migkou, Magdalini
    Psimenou, Erasmia
    Grapsa, Irini
    Matsouka, Charis
    Barmparousi, Despina
    Terpos, Evangelos
    Dimopoulos, Meletios Athanasios
    LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 890 - 895
12345